FGFR Inhibitor
Aug 11, 2026
Sobi Partners with Innate Pharma to License Lacutamab for T-Cell Lymphoma; Yochanra Makes Global Debut in China as First Innovative Drug Designed to Overcome FGFR Inhibitor Resistance; Replimune Secures FDA Accelerated Approval for TUDRIQEV Plus Nivolumab in Advanced Cutaneous Melanoma; FDA Accepts Supplemental Biologics License Application for ENFLONSIA to Broaden RSV Indication in Young Children; Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals
Sobi Licenses Lacutamab from Innate Pharma to Advance Treatment of T-Cell Lymphoma Swedish Orphan Biovitrum AB (Sobi®) and Innate Pharma SA have announced a strategic partnership aimed at enabling the initiation of the TELLOMAK-3 confirmatory Phase 3 trial of lacutamab in cutaneous T-cell lymphoma (CTCL). The st...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
